Study registration: *
Publication Vaishya R, SSRN, 2021
Dates: 2021-01-16 to 2021-06-15
Funding: No specific funding
Conflict of interest: no COI (None)

Methods

Study design:Cohort
Description of participants: Vaccinated healthcare workers in 43 hospitals in 24 Indian cities
Inclusion criteria:
  • HCW working at an Apollo Group hospital
  • received 1 or 2 doses of either ChAdOx (Covishield, Serum Institute, India) or Vero cell vaccine (Covaxin, Bharat Biotech, India)

Exclusion criteria:
  • All participants with asymptomatic PVIs
  • non-vaccinated HCWs
  • those with negative RT-PCR test results

Follow-up duration (months): 5
Vaccines:
  • 2 doses of ChAdOx1-S
Variant description :
Variant name: Delta
Evidence: Indirect evidence (prevalence of variant in the population: 1 to 99%)
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing stated: NR
Data accessibility: Dr. (Prof.) Raju Vaishya Email: raju_vaishya@apollohospitalsdelhi.com
General comment Concerns mainly about the possibility of uncontrolled confounding; there are also some missing data with a lack of further information about these.